Progesterone for transgender wome

Phase 4

• Conditions: Transgender; Sleep; Anxiety; Metabolic and Endocrine - Other endocrine disorders

• Registration Number: ACTRN12620001130954
• Lead Sponsor: Austin Health

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-10-30
• Last Update Posted: 9 November 2020

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: Female
• Target Recruitment: 38

Inclusion Criteria

Transfeminine individuals aged 18-70 years treated with estradiol for at least six months.

Exclusion Criteria

1.Contraindications to micronised progesterone.
2.History of orchidectomy.
3.Sunflower seed allergy.
4.Known, suspected, or history of breast cancer.
5.Active deep vein thrombosis, pulmonary embolism or history of these conditions.
6.Active arterial thromboembolic disease or history of these conditions.
7.Known liver dysfunction or disease.
8.Recreational drug use, alcohol dependence, known HIV/AIDS or any disease that is likely lead to serious illness or death within the study period.
9.Inability to understand sufficient English to provide informed consent or participate in the trial.

Study & Design

• Study Type: Interventional
• Study Design: Not specified